Bioequivalence Study of 100 mg/5 mL Cefixime Trihydrate Dry Syrup, Manufactured by PT. Pharma Laboratories (CEFIXIME TRIHYDRATE) in Comparison with the Innovator’s Oral Suspension (Suprax®), Manufactured by Odan Laboratories Ltd., Montreal, Canada H9R 2Y6, Registered Trademark of Astellas Pharma Inc., Osaka, Japan
Tahapan Penelitian : Complete
Sponsor:
PT Pharma Laboratories
Mitra Pelaksana:
Econolab
No Registry
INA-Y9PKF04
Tanggal Input Registry : 09-02-2024
| Tracking Information | |
|---|---|
| Tanggal Antisipasi Studi | 02-11-2019 |
| Outcome Primer | AUC0-t and Cmax |
| Outcome Skunder | AUC0-∞, Tmax, T1/2 |
| Descriptive Information | |
| Judul Penelitian Popular | Bioequivalence Study of 100 mg/5 mL Cefixime Trihydrate Dry Syrup, Manufactured by PT. Pharma Laboratories (CEFIXIME TRIHYDRATE) in Comparison with the Innovator’s Oral Suspension (Suprax®), Manufactured by Odan Laboratories Ltd., Montreal, Canada H9R 2Y6, Registered Trademark of Astellas Pharma Inc., Osaka, Japan |
| Judul Penelitian Ilmiah | Bioequivalence Study of 100 mg/5 mL Cefixime Trihydrate Dry Syrup, Manufactured by PT. Pharma Laboratories (CEFIXIME TRIHYDRATE) in Comparison with the Innovator’s Oral Suspension (Suprax®), Manufactured by Odan Laboratories Ltd., Montreal, Canada H9R 2Y6, Registered Trademark of Astellas Pharma Inc., Osaka, Japan |
| Jenis Penelitian | Interventional |
| Intervensi | Single dose of 10 mL of reconstituted 100 mg/5 mL Cefixime Dry Syrup (CEFIXIME TRIHYDRATE), Manufactured PT Pharma Laboratories |
| Jumlah Subyek Penelitian | 22 |
| Recruitment Information | |
| Eligibility Criteria | Inclusion Criteria: Able to participate, communicate well with the investigators and agree to sign an informed consent; Healthy male/female subjects as determined by the medical screening assessments; Aged 18-55 years of age; Body mass index (BMI) is in the range of 18-25 kg/m²; Systolic blood pressure:100-120 mmHg; Diastolic blood pressure: 60-80 mmHg; Pulse rate 60-90 bpm; Normal electrocardiogram (ECG); Clinical laboratory results have to be within normal range. Medical judgement of responsible physician determined any laboratory finding beyond its standard value.Exclusion Criteria: Pregnant or lactating women (urinary pregnancy test were applied to female subjects when screening and just before taking the test or innovator drug); Known hypersensitivity or contraindication to the study drug; intake of any prescription drug or non-prescription drug/food supplement/herbal medicine within 7 days of this study’s first dosing day; History of any bleeding or coagulation disorders; Any surgical or medical condition (present or history) which might significantly alters the absorption, distribution, metabolism or excretion of the study drug, e.g. gastrointestinal diseases including gastric or duodenal ulcers or history of gastric surgery; A donation or loss of 300 mL (or more) of blood within 3 months before this study’s first dosing day; A positive Hepatitis B surface antigen (HBsAg), HCV, HIV test result; History of drug or alcohol abuse within 12 months prior to this study; Heavy Smoker (more than 10 cigarettes a day); Clinically have significant bleeding within 3 months prior to the study; Participation in a previous study within 3 months of this study’s first dosing day. |
| Administrative Information | |
| Nomor Persetujuan Etik | 1048./UN2.F1/ETIK/2018 |
| Nomor Persetujuan Material Transfer Agreement | Not applicable |
| Nomor Persetujuan Pelaksanaan Uji Klinik | PPUK/PPUB number |
| Other Study ID Numbers | PRO-233/18/ECL |
| Contact Person | Ni Made Dwi Wulandari |